E-News 2007
NCI Immunotherapy Workshop Develops Ranked List of Agents with High Potential
Discussions held at the National Cancer Institute's "Immunotherapy Agent Workshop" generated a list of 20 ranked agents with high potential for use in treating cancer. Despite substantial demonstrated immunological efficacy, these 20 listed agents are not currently available for testing to broad audiences of cancer patients. It is believed that the Workshop's findings will encourage future therapeutic endeavors utilizing these high-potential agents. Workshop participants included several iSBTc members, including the program's co-chair, Dr. Martin A Cheever from the University of Washington. To view a PDF of the resulting manuscript, including the complete listing of the 20 ranked agents, please click HERE
Hot Topic Session Added to 22nd Annual Meeting: "Dendreon Debate"
iSBTC 22nd Annual Meeting attendees will need to adjust their schedules for Sunday, November 4, 2007. Following the conclusion of the "Vaccines/Dendritic Cells" session and beginning at approximately 11:15 AM, iSBTc has added a hot topic session focusing exclusively on the recent developments surrounding Dendreon's proposed tumor vaccine. The session will also host a moderate panel discussion. Confirmed speakers and a session outline will be announced in the weeks ahead. For more information about the Annual Meeting, please click HERE
iSBTc Mini-Symposium Addresses Critical Component for Future Combination Therapies of Cancer
View Mini-Symposium Report 
Targeted and immune agents will serve as critical components for future combination therapies of cancer, according to a report resulting from the International Society for Biological Therapy of Cancer's (iSBTc) "Mini-symposium on Biologic Effects of Targeted Therapeutics." Read More...
|
iSBTc Mini-Symposium Addresses Critical Component
for Future Combination Therapies of Cancer (continued...)
"This Mini-symposium represented an initial look into what is likely to be an important area of clinical and translational investigation in the future and a critical component to developing treatment regimens involving combinations of targeted and immune agents," observes Dr. Michael B. Atkins, iSBTc Past-President and Mini-symposium Co-chair. "In this way, this Mini-symposium laid the groundwork for the upcoming iSBTc Workshop on Combination Therapy."
Held October 26, 2006 in Los Angeles, California, the Mini-symposium highlighted an emerging appreciation and understanding of the mechanistic complexity associated with the use of targeted therapies. The resulting "Report on iSBTc Mini-symposium on Biologic Effects of Targeted Therapeutics" will be published in the September 2007 issue of the Journal of Immunotherapy and can also be viewed in its entirety on the iSBTc website (www.isbtc.org). Ideas discussed at the Mini-symposium will be revisited at this year's "Workshop on Future Opportunities for Combination Biological Therapy of Cancer" to be held Thursday, November 1, 2007 in Boston, Massachusetts.
The Mini-symposium ultimately sought to inform and influence basic science efforts and discussions, rationally design combination treatment regimens, and optimally employ correlative studies in the context of ongoing and future clinical investigations by discussing various topics related to the biologic effects of targeted therapeutics. According to the report summary, the off-target biologic effects of targeted therapies are frequent and may be crucial contributors to patient outcomes. Although there are conceptual and practical challenges to understanding, leveraging and controlling such effects, their successful manipulation may lead to improved cancer treatments.
Founded in 1984, the International Society for Biological Therapy of Cancer is an organization of clinicians, researchers, students, post-doctoral fellows, and allied health professionals dedicated to improving cancer patient outcomes by advancing the development and application of biological therapy through interaction, innovation, and leadership. With several high-quality scientific meetings and numerous networking opportunities unique to the Society, iSBTc has developed into the premier destination for interaction and innovation in the cancer biologics and cancer immunotherapy communities.
|
iSBTc 23rd Annual Meeting and Associated Programs:
Oct. 30 - Nov. 2, 2008 in San Diego, CA
The International Society for Biological Therapy of Cancer (iSBTc) is excited to announce our return to San Diego, CA on October 30 - November 2, 2008 for the iSBTc 23rd Annual Meeting and Associated Programs. Mark your calendars now for the premier event focused on cancer biologics and tumor immunology.
The iSBTc Annual Meeting is an abstract driven program and serves as the primary iSBTc-sponsored event for the year. Annual Meetings offer an interactive educational environment, high-caliber invited speakers, oral abstract presentations, and unique opportunities for collaborative interaction with program faculty and colleagues.
Other programs held in conjunction with the iSBTc Annual Meeting have included: interactive, topical Workshops focused on cutting-edge developments in the field; Primers designed to provide basic didactic training regarding tumor immunology and biological therapy for students, fellows, and allied health professionals; Dinner Symposia presentations that address aspects of biological therapy with a specific disease-oriented focus. Collectively, these programs provide a wealth of opportunities for scientific exchange and dialogue with leaders in the field.
Click here for more information
DAMP Satellite Abstracts Now Available for Viewing
The International Society for Biological Therapy of Cancer (iSBTc) and the Clinical Immunology Society (CIS) are proud to present the abstracts from the Damage Associated Molecular Pattern Molecules Satellite Symposia held June 7, 2007 at the Sheraton San Diego Hotel & Marina in San Diego, CA. To view both the schedule and corresponding abstracts from the DAMP Satellite, please click HERE.
iSBTc Publishes 21st Annual Meeting and Associated Programs Meeting Highlights
The organizers of the iSBTc 21st Annual Meeting, Primer on Tumor Immunology and Biological Therapy, and Mini-Symposium on Biologic Effects of Targeted Therapeutics are proud to announce the publication of "Immunotherapy Comes of Age: Overview of the 21st Annual Meeting and Associated Programs of the International Society for Biological Therapy of Cancer" in the March issue of Expert Opinion on Biological Therapy. This document reviews the highlights of these three scientific meetings. To view it in its entirety, please click HERE.
